These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25891734)

  • 1. Thymoglobulin for steroid-resistant immune-mediated graft dysfunction during simeprevir-based antiviral treatment for post-transplantation hepatitis C: case report.
    Takeishi K; Ikegami T; Yoshizumi T; Itoh S; Harimoto N; Harada N; Tsujita E; Kimura Y; Yamashita Y; Saeki K; Oki E; Shirabe K; Maehara Y
    Transplant Proc; 2015 Apr; 47(3):794-5. PubMed ID: 25891734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report.
    Kawaoka T; Imamura M; Kan H; Fujino H; Fukuhara T; Kobayashi T; Honda Y; Naeshiro N; Hiramatsu A; Tsuge M; Hayes CN; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Tashiro H; Ohdan H; Chayama K
    Transplant Proc; 2015 Apr; 47(3):809-14. PubMed ID: 25891736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study.
    Tanaka T; Sugawara Y; Akamatsu N; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Kurosaki M; Izumi N; Kokudo N
    J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):144-50. PubMed ID: 25338946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De novo autoimmune hepatitis subsequent to switching from type 2b to type 2a alpha-pegylated interferon treatment for recurrent hepatitis C after liver transplantation: report of a case.
    Takeishi K; Shirabe K; Toshima T; Ikegami T; Morita K; Fukuhara T; Motomura T; Mano Y; Uchiyama H; Soejima Y; Taketomi A; Maehara Y
    Surg Today; 2011 Jul; 41(7):1016-9. PubMed ID: 21748625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute Graft Rejection and Formation of De Novo Donor-Specific Antibodies Triggered by Low Cyclosporine Levels and Interferon Therapy for Recurrent Hepatitis C Infection After Liver Transplantation: A Case Report.
    Nakano R; Ohira M; Ishiyama K; Ide K; Kobayashi T; Tahara H; Shimizu S; Arihiro K; Imamura M; Chayama K; Tanaka Y; Ohdan H
    Transplant Proc; 2017 Sep; 49(7):1634-1638. PubMed ID: 28838454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin.
    Stanca CM; Fiel MI; Kontorinis N; Agarwal K; Emre S; Schiano TD
    Transplantation; 2007 Jul; 84(2):180-6. PubMed ID: 17667809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin.
    Neumann U; Puhl G; Bahra M; Berg T; Langrehr JM; Neuhaus R; Neuhaus P
    Transplantation; 2006 Jul; 82(1):43-7. PubMed ID: 16861940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate mofetil may induce prolonged severe anemia during pegylated-interferon/ribavirin/simeprevir therapy in liver transplant recipients.
    Kogiso T; Tokushige K; Hashimoto E; Taniai M; Omori A; Kotera Y; Egawa H; Yamamoto M; Shiratori K
    Clin J Gastroenterol; 2015 Jun; 8(3):156-61. PubMed ID: 25963122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
    Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
    Stravitz RT; Shiffman ML; Sanyal AJ; Luketic VA; Sterling RK; Heuman DM; Ashworth A; Mills AS; Contos M; Cotterell AH; Maluf D; Posner MP; Fisher RA
    Liver Transpl; 2004 Jul; 10(7):850-8. PubMed ID: 15237368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with efficacy of pegylated interferon-α plus ribavirin for chronic hepatitis C after renal transplantation.
    Li LF; Shi KQ; Lin YQ; Wang LR; He JP; Braddock M; Chen YP; Zheng MH
    Gene; 2014 Jul; 544(2):101-6. PubMed ID: 24793583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation.
    Dinges S; Morard I; Heim M; Dufour JF; Müllhaupt B; Giostra E; Clavien PA; Mentha G; Negro F;
    Transpl Infect Dis; 2009 Feb; 11(1):33-9. PubMed ID: 19144096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment for recurrent hepatitis C virus infection after liver transplantation.
    Balbi E; Leal CR; Pacheco-Moreira LF; Pousa FS; Covelo MC; Gonzalez AC; Oliveira PV; Agoglia L; Roma J; Cariús LP; Enne M
    Transplant Proc; 2009 Apr; 41(3):891-4. PubMed ID: 19376381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological features of hepatitis C virus disease after living donor liver transplantation: relationship with in situ hybridisation data.
    Masuda Y; Nakazawa Y; Matsuda K; Sano K; Mita A; Ohno Y; Urata K; Ikegami T; Miwa S; Miyagawa S
    Pathology; 2011 Feb; 43(2):156-60. PubMed ID: 21233678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
    Dieterich D; Rockstroh JK; Orkin C; Gutiérrez F; Klein MB; Reynes J; Shukla U; Jenkins A; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; De La Rosa G; Tambuyzer L; Jessner W
    Clin Infect Dis; 2014 Dec; 59(11):1579-87. PubMed ID: 25192745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation.
    Nair S; Lipscomb J; Eason J
    Transplantation; 2008 Aug; 86(3):418-22. PubMed ID: 18698245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.
    Antonini TM; Furlan V; Teicher E; Haim-Boukobza S; Sebagh M; Coilly A; Bonhomme-Faivre L; Roque-Afonso AM; Vittecoq D; Samuel D; Taburet AM; Duclos-Vallée JC
    AIDS; 2015 Jan; 29(1):53-8. PubMed ID: 25387314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimitochondrial antibody serocoversion post-liver transplant during hepatitis C treatment with peginterferon α, ribavirin and telaprevir.
    Marquez-Azalgara V; Hussaini T; Erb SR; Yoshida EM
    Ann Hepatol; 2014; 13(5):565-7. PubMed ID: 25152991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple therapy using direct-acting agents for recurrent hepatitis C after liver transplantation: a single-center experience.
    Ikegami T; Yoshizumi T; Soejima Y; Harimoto N; Itoh S; Takeishi K; Uchiyama H; Kawanaka H; Yamashita YI; Tsujita E; Harada N; Oki E; Saeki H; Kimura Y; Shirabe K; Maehara Y
    Transplant Proc; 2015 Apr; 47(3):730-2. PubMed ID: 25891720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.